Physician profile
Liam Eamonn Boyle
NPI 1437158755
$393.50
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $85.00 · 2021: $26.36.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $160.90 | 2019-2020 | |
| Puma Biotechnology, INC. | $68.83 | 2019 | |
| Janssen Pharmaceuticals, INC | $46.69 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $24.70 | 2019 | |
| Janssen Scientific Affairs, LLC | $18.59 | 2019 | |
| Abbvie INC. | $14.71 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.86 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $11.65 | 2021 | |
| Heron Therapeutics, INC. | $11.53 | 2019 | |
| Celgene Corporation | $11.21 | 2019 | |
| Amag Pharmaceuticals, INC. | $10.83 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Research and ownership
$4,578.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liam Boyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.